Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in the US, with more than 1.6 million people affected. Wet AMD is a more severe progression of AMD, affecting 10 percent of patients with AMD. One of the treatments for wet AMD is ranibizumab (trade name Lucentis©); however, these treatments require frequent injections into the affected eye. 

We believe that gene therapy offers a potential long-term solution to treat wet AMD with one injection, and there is a strong rationale for combination therapy to become the standard of care in wet AMD.  We have defined our preferred target profile and are proceeding with a comprehensive review of possible targets.

Campochiaro gene transfer for AMD and ME Gene Ther 2012. 

Contact Us

Alachua – Headquarters
14193 NW 119th Terrace, Suite #10
Alachua, Florida 32615
386.462.2204
Map
Cambridge
One Kendall Square, 1400W, Suite B14305
Cambridge, MA 02139
617.843.5728
Map

Please enter the letters from the image below in order to prevent spam.